Literature DB >> 3429215

A multiparametric index of platelet in vitro aggregation in cerebrovascular disease.

P P Gazzaniga1, P Ferroni, C Mina, F M Pulcinelli, P A Rizzo.   

Abstract

148 patients with various forms of cerebrovascular disease (CVD) were studied by means of a multiparametric analysis of in vitro platelet aggregation, based on the following six parameters: ADP and epinephrine primary and secondary aggregation thresholds and percent maximum aggregation induced by optimal concentrations of ADP and epinephrine. These patients were assigned to four study groups, according to clinical diagnosis supported by CT scan, of transient ischemic attack and reversible neurological deficit (TIA-RIND), or completed stroke, in the presence or absence respectively of antiplatelet medical treatment at the time of the study. A statistically significant increase of the in vitro platelet aggregation was found in 44.4% of the untreated TIA-RIND patients and in 33.9% of the untreated stroke patients. However this last group showed a higher percentage of very marked hyperaggregation. Differences between the two treated study groups and controls were not significant. No difference was found in collagen- and ristocetin-induced aggregation between the patient groups and the controls.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3429215     DOI: 10.1007/BF02333662

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  14 in total

1.  A classification and outline of cerebrovascular diseases. II.

Authors: 
Journal:  Stroke       Date:  1975 Sep-Oct       Impact factor: 7.914

2.  Randomised trial of pentoxifylline versus acetylsalicylic acid plus dipyridamole in preventing transient ischaemic attacks.

Authors:  E Herskovits; A Vazquez; A Famulari; R Smud; L Tamaroff; H Fraiman; A M Gonzalez; J Vila; V Matera
Journal:  Lancet       Date:  1981-05-02       Impact factor: 79.321

3.  Platelet activation in acute cerebral ischaemia. Serial measurements of platelet function in cerebrovascular disease.

Authors:  J H Dougherty; D E Levy; B B Weksler
Journal:  Lancet       Date:  1977-04-16       Impact factor: 79.321

Review 4.  Platelet inhibitors for TIAs. A review of prospective drug trial results.

Authors:  M Ramirez-Lassepas
Journal:  Postgrad Med       Date:  1984-04       Impact factor: 3.840

Review 5.  Therapeutical aspects of cerebrovascular disease.

Authors:  H Lechner; E Ott; G Bertha
Journal:  Eur Neurol       Date:  1983       Impact factor: 1.710

6.  Platelet aggregability measured by screen filtration pressure method in cerebrovascular diseases.

Authors:  I Kobayashi; T Fujita; H Yamazaki
Journal:  Stroke       Date:  1976 Jul-Aug       Impact factor: 7.914

7.  Treatment after transient ischemic attacks: a comparison between anticoagulant drug and inhibition of platelet aggregation.

Authors:  A Gårde; K Samuelsson; H Fahlgren; E Hedberg; L G Hjerne; J Ostman
Journal:  Stroke       Date:  1983 Sep-Oct       Impact factor: 7.914

8.  Platelet aggregation in focal cerebral ischemia -a clinical study.

Authors:  P E Hansen; J H Hansen; S Stenbjerg
Journal:  Acta Neurol Scand       Date:  1982-03       Impact factor: 3.209

Review 9.  Aspirin and other platelet-aggregation inhibiting drugs.

Authors:  A S Gallus
Journal:  Med J Aust       Date:  1985-01-07       Impact factor: 7.738

10.  "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.

Authors:  M G Bousser; E Eschwege; M Haguenau; J M Lefaucconnier; N Thibult; D Touboul; P J Touboul
Journal:  Stroke       Date:  1983 Jan-Feb       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.